The public health impact of malignant melanoma continues to increase. It has been estimated that 59 580 newly diagnosed cases of invasive melanoma and an additional 46 170 cases of in situ melanoma will occur in the United States in 2005.1 Currently, 1 in 62 people in the United States will develop invasive melanoma during their lifetime (up from 1 in 1500 in 1930), and should the current rate of increase in incidence continue, by 2010 the lifetime risk will increase to 1 in 50 (Figure 1). If in situ cases are included, the lifetime risk of a US patient developing melanoma is 1 in 34. The annual cost of treating skin cancer in the Medicare population alone in the United States is now estimated at $1 billion,2 with 90% of treatment costs associated with therapy for advanced disease.3
Evolution of the lifetime risk of a US inhabitant developing invasive melanoma.
Five-year survival in patients with newly diagnosed stage I melanoma by year in the United States.
Incidence and mortality rates for invasive melanoma in the United States.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Dermatology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 50
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
The Rational Clinical Examination
Make the Diagnosis: Melanoma
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.